SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Enhertu Breast Cancer Treatment: Major Advances in Invasive Disease-Free Survival
What is the impact of Enhertu breast cancer treatment for patients with early-stage HER2-positive breast cancer? Enhertu breast cancer treatment has shown a significant improvement in invasive disease-free survival (iDFS) compared to the prior standard, trastuzumab emtansine (T-DM1). According to...
Transforming Healthcare with the Gene Therapy Access Model
The gene therapy access model is a groundbreaking federal-state collaborative framework designed to improve how transformative treatments are distributed and financed, particularly within Medicaid. This innovative approach answers a key question for patients and policymakers: How can we ensur...
PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic Infrastructure and Care
Yesterday PhRMA announced steps to boosting patient access to treatments. The announcement showcases the U.S. biopharmaceutical industry’s initiative to enhance patient access and stimulate economic growth. The announcement outlines a remarkable $500 billion in new U.S. infrastructure spending. I...